Crinetics Pharmaceuticals (CRNX) Operating Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Operating Expenses history runs 10 years deep, the most recent figure standing at $151.1 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 35.2% year-over-year to $151.1 million in Q1 2026; TTM through Mar 2026 was $563.8 million, a 49.36% increase from a year earlier, with the FY2025 full-year figure at $524.5 million, up 54.3% from the prior year.
• Operating Expenses climbed to $151.1 million in Q1 2026 per CRNX's latest filing, from $139.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $151.1 million in Q1 2026 and bottomed at $37.0 million in Q1 2022.
• The 5-year median for Operating Expenses is $74.2 million (2024), against an average of $83.2 million.
• Across the five-year window, Operating Expenses jumped 66.68% in 2022 and gained 24.14% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $48.3 million in 2022, then grew by 29.82% to $62.7 million in 2023, then surged by 51.21% to $94.7 million in 2024, then soared by 47.58% to $139.8 million in 2025, then gained by 8.07% to $151.1 million in 2026.
• Per Business Quant, the three latest CRNX Operating Expenses figures stand at $151.1 million (Q1 2026), $139.8 million (Q4 2025), and $142.7 million (Q3 2025).